

XP-002195568

BEST AVAILABLE COPY

AN - 1997-037972 [04]
AP - JP19950127813 19950526

CPY - SAKA

DC - B05

FS - CPI

IC - A61K38/00

MC - B10-B02J B14-A01 B14-E07 B14-K01

M2 - [01] H1 H100 H181 J0 J013 J1 J171 J3 J372 M280 M312 M313 M321 M331
M332 M340 M342 M343 M349 M381 M392 M416 M431 M620 M781 M782 M903 M904
P220 P820; 9704-09201-M 9704-09201-U

- [02] J0 J013 J1 J171 J3 J372 M280 M312 M313 M321 M331 M332 M340 M342
M343 M349 M381 M392 M416 M431 M620 M781 M782 M903 M904 P220 P820;
9704-09202-M 9704-09202-U

- [03] H1 H100 H181 J0 J013 J1 J171 J3 J372 M280 M311 M313 M321 M332
M342 M343 M349 M381 M392 M416 M431 M620 M781 M782 M903 M904 P220 P820;
R10426-M R10426-U

PA - (SAKA) OTSUKA SEIYAKU KOGYO KK

PN - JP8295633 A 19961112 DW199704 A61K38/00 004pp

PR - JP19950041770 19950301

XA - C1997-011919

XIC - A61K-038/00

AB - J08295633 An agent for the prevention of complications on a patient in
a state of highly enhanced protein metabolism comprises at least one
dipeptide constituted with glutamine.

- Pref. dipeptides are glycyl-L-glutamine, L-glutaminy-L-alanine, and
esp. L-alanyl-L-glutamine.

- USE/ADVANTAGE - The dipeptide is for the treatment of a patient, esp.
treated under total parenteral nutrition (TPN) in the intensive care
unit (claimed). Examples of such complications are serious infections
such as bacteraemia and septicemia, acute respiratory insufficiency
syndrome and acidosis. A preferable dose is 0.5-7.4 mmol/kg/day.
Complications that occur in a patient treated as above such as
increased susceptibility to the invasion of microorganisms through
weakened intestinal membrane or via a catheter can be suppressed by
giving the dipeptide as a nutrient.

- In an example, an artificial scald, of which the area accounted for 12
% of the total body surface, was made on a male Wistar rat on the
back, and the rat was given 22.5 % aqueous soln. of
L-alanyl-L-glutamine at a dosage of 30 mmol/kg/day for 5 days under
the TPN control. From the rat was removed Lymponodules, which was
homogenized and the homogenate was incubated on an agar medium at 35
deg. C for 24 hours to form colonies of intestinal microorganisms: 66
% of the rats which had been received the peptide were found positive
to the bacterial infection, as opposed to 87 % for rats which had been
given a transfusion nutrient soln. instead.(Dwg.0/0)

CN - 9704-09201-M 9704-09201-U 9704-09202-M 9704-09202-U R10426-M R10426-U

IW - AGENT PREVENT COMPLICATED PATIENT STATE HIGH ENHANCE PROTEIN
METABOLISM CONTAIN GLUTAMINE DI PEPTIDE GLYCYL GLUTAMINE USEFUL TREAT
SEPTICAEMIA

IKW - AGENT PREVENT COMPLICATED PATIENT STATE HIGH ENHANCE PROTEIN
METABOLISM CONTAIN GLUTAMINE DI PEPTIDE GLYCYL GLUTAMINE USEFUL TREAT

SEPTICAEMIA

NC - 001

OPD - 1995-03-01

ORD - 1996-11-12

PAW - (SAKA) OTSUKA SEIYAKU KOGYO KK

TI - Agent for prevention of complications on patient in a state of highly enhanced protein metabolism - contains a glutamine di:peptide e.g. glycyl-L-glutamine, useful to treat e.g. septicaemia

BEST AVAILABLE COPY